Biotech · Public company · San Diego, CA, US
BioAtla, Inc.
Ticker BCAB · SEC CIK 0001826892
Track this companyFree. Adds BioAtla, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials61 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline14
- BA3071Phase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- CAB-AXL-ADCPhase 2 · Non-Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CAB-AXL-ADCPhase 2 · Undifferentiated Pleomorphic SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- CAB-ROR2-ADCPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- Evalstotug (BA3071)Phase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- Ozuriftamab VedotinPhase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- PD-1 inhibitorPhase 2 · Non-Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PD-1 inhibitorPhase 2 · Undifferentiated Pleomorphic SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- Pemetrexed (Alimta)Phase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- BA3182Phase 1 · Advanced AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.PHASE1 · RECRUITING · started Jul 14, 2023ClinicalTrials.gov NCT05808634 · fetched Nov 12, 2026
- A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckPHASE2 · COMPLETED · started Dec 13, 2022ClinicalTrials.gov NCT05271604 · fetched Nov 12, 2026
- A Phase 1/2 Study of BA3071 in Patients With Solid TumorsPHASE1_PHASE2 · UNKNOWN · started Aug 3, 2022ClinicalTrials.gov NCT05180799 · fetched Nov 12, 2026
- CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCPHASE2 · COMPLETED · started Mar 17, 2021ClinicalTrials.gov NCT04681131 · fetched Nov 12, 2026
- CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)PHASE1_PHASE2 · COMPLETED · started Jun 27, 2018ClinicalTrials.gov NCT03504488 · fetched Nov 12, 2026
- CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With SarcomaPHASE1_PHASE2 · COMPLETED · started Feb 15, 2018ClinicalTrials.gov NCT03425279 · fetched Nov 12, 2026
SEC filings12
- S-1 · S-1SEC EDGAR · filed Oct 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 28, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 16, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 2, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 23, 2026 · fetched Nov 12, 2026